Letter

What happened to the polypill?

Why is there more heat than light concerning the polypill?

BMJ 2008; 337 doi: 10.1136/bmj.a2162 (Published 20 October 2008)
Cite this as: BMJ 2008;337:a2162

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Anthony Rodgers, professor1,
  2. Anushka Patel, director2
  1. 1School of Population Health, University of Auckland, PB92019, Auckland, New Zealand
  2. 2Cardiovascular Division, George Institute for International Health, University of Sydney, Sydney, NSW 2000, Australia
  1. a.rodgers{at}auckland.ac.nz

    Watts’s question—why are there still so few polypill trials?—is reasonable.1

    In 2001 epidemiologist Richard Peto facilitated a meeting between the World Health Organization and the Wellcome Trust to discuss development of fixed dose combination products in secondary prevention of cardiovascular disease.2 Yusuf noted the potential for a combination treatment to reduce cardiovascular risk by three quarters in the Lancet in 2002.3 …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular